Immune system and glucose metabolism interaction in schizophrenia: A chicken-egg dilemma

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 48, Issue , 2014, Pages 287-294

  Steiner, Johann ^a,b   Bernstein, Hans Gert ^a   Schiltz, Kolja ^a,b   Müller, Ulf J ^a   Westphal, Sabine ^a   Drexhage, Hemmo A ^c   Bogerts, Bernhard ^a,b  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b Center for Behavioral Brain Sciences   (Germany)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Glucose metabolism; Immune system; Lymphocytes; Microglia; Mononuclear phagocyte system; Schizophrenia

Indexed keywords

C REACTIVE PROTEIN; CLOZAPINE; GAMMA INTERFERON; INSULIN RECEPTOR; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; OLANZAPINE; PROTEIN KINASE B; PROTEIN S100B; SOLUBLE INTERLEUKIN 2 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE BEHAVIOR; ARTICLE; AUTOIMMUNE THYROIDITIS; BEHAVIOR CHANGE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ACTIVATION; CONVULSIVE THERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE ASSOCIATION; ENERGY EXPENDITURE; ENZYME PHOSPHORYLATION; GENETIC PREDISPOSITION; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; IMMUNE SYSTEM; IMMUNOREACTIVITY; INSULIN DEPENDENT DIABETES MELLITUS; MACROPHAGE; METABOLIC SYNDROME X; MICROGLIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOGENESIS; PROTEIN BLOOD LEVEL; REGULATORY MECHANISM; SCHIZOPHRENIA; SELFISH BRAIN THEORY; SIGNAL TRANSDUCTION; T LYMPHOCYTE; THEORY; VISCERAL OBESITY;

5HT2C RECEPTOR; A CALCIUM-BINDING MEMBER OF A FAMILY OF PROTEINS THAT ARE 100% SOLUBLE IN AMMONIUM SULFATE AT NEUTRAL PH; A SERINE-THREONINE PROTEIN KINASE; A SUBTYPE OF 5-HYDROXYTRYPTAMINE RECEPTOR THAT BINDS THE NEUROTRANSMITTER SEROTONIN; AGOUTI-RELATED PEPTIDE; AGRP; AITD; AKT1; ARC; AUTOIMMUNE THYROID DISEASE; BMI; BODY-MASS-INDEX; C-REACTIVE PROTEIN; C-TERMINAL PDZ DOMAIN LIGAND OF NEURONAL NITRIC OXIDE SYNTHASE; CAPON; CART; CCK; CD; CEREBROSPINAL FLUID; CHOLECYSTOKININ; CLUSTER OF DIFFERENTIATION; COCAINE- AND AMPHETAMINE-REGULATED TRANSCRIPT; CORTICOTROPIN-RELEASING HORMONE; CRH; CRP; CSF; DCS; DENDRITIC CELLS; FDG-PET; FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY; FMRI; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE ENCODING LAMIN A/C; GLP-1; GLUCAGON-LIKE PEPTIDE-1; GLUCOSE METABOLISM; GLUT4; HYPOTHALAMIC ARCUATE NUCLEUS; IFN-Γ; IGF-1; IL; IMMUNE SYSTEM; INSULIN-LIKE GROWTH FACTOR-1; INSULIN-SENSITIVE GLUCOSE TRANSPORTER 4; INTERFERON-GAMMA; INTERLEUKIN; LMNA; LYMPHOCYTES; MAJOR HISTOCOMPATIBILITY COMPLEX; MCH; MELANIN-CONCENTRATING HORMONE; MHC; MICROGLIA; MONONUCLEAR PHAGOCYTE SYSTEM; MPS; NEUROPEPTIDE Y; NPY; NTS; NUCLEUS TRACTUS SOLITARII; PBMCS; PEPTIDE YY; PERIPHERAL BLOOD MONONUCLEAR CELLS; POLYI:C; POLYRIBOINOSINIC-POLYRIBOCYTIDILIC ACID; POMC; PRO-OPIOMELANOCORTIN; PYY; REGULATOR OF G-PROTEIN SIGNALING 4; RGS4; S100B; SCHIZOPHRENIA; SIL-2R; SOLUBLE IL-2 RECEPTOR; SOLUBLE RECEPTOR FOR ADVANCED GLYCATION PRODUCTS; SRAGE; TGF-Β; THYROTROPIN RELEASING HORMONE; TNF-Α; TRANSFORMING GROWTH FACTOR-BETA; TRH; TUMOR NECROSIS FACTOR-ALPHA;

CYTOKINES; GLUCOSE METABOLISM DISORDERS; HUMANS; IMMUNE SYSTEM; SCHIZOPHRENIA;

EID: 84888858969     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.09.016     Document Type: Article

References (140)

1. Adami C., Bianchi R., Pula G., Donato R. S100B-stimulated NO production by BV-2 microglia is independent of RAGE transducing activity but dependent on RAGE extracellular domain. Biochim Biophys Acta 2004, 1742:169-177.
2. Alliot F., Godin I., Pessac B. Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res 1999, 117:145-152.
3. Badenhoop K., Tonjes R.R., Rau H., Donner H., Rieker W., Braun J., et al. Endogenous retroviral long terminal repeats of the HLA-DQ region are associated with susceptibility to insulin-dependent diabetes mellitus. Hum Immunol 1996, 50:103-110.
4. Bale T.L., Baram T.Z., Brown A.S., Goldstein J.M., Insel T.R., McCarthy M.M., et al. Early life programming and neurodevelopmental disorders. Biol Psychiatry 2010, 68:314-319.
5. Banks W.A. Blood-brain barrier and energy balance. Obesity (Silver Spring) 2006, 14(Suppl. 5):234S-237S.
6. Baptista T., Rangel N., El Fakih Y., Uzcategui E., Galeazzi T., Beaulieu S., et al. Rosiglitazone in the assistance of metabolic control during olanzapine administration in schizophrenia: a pilot double-blind, placebo-controlled, 12-week trial. Pharmacopsychiatry 2009, 42:14-19.
7. Batterham R.L., Cowley M.A., Small C.J., Herzog H., Cohen M.A., Dakin C.L., et al. Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 2002, 418:650-654.
8. Bayer T.A., Buslei R., Havas L., Falkai P. Evidence for activation of microglia in patients with psychiatric illnesses. Neurosci Lett 1999, 271:126-128.
9. Bernstein H.G., Ernst T., Lendeckel U., Bukowska A., Ansorge S., Stauch R., et al. Reduced neuronal expression of insulin-degrading enzyme in the dorsolateral prefrontal cortex of patients with haloperidol-treated, chronic schizophrenia. J Psychiatr Res 2009, 43:1095-1105.
10. Betterle C., Zanchetta R. Update on autoimmune polyendocrine syndromes (APS). Acta bio-medica: Atenei Parmensis 2003, 74:9-33.
11. Beumer W, Drexhage RC, De Wit H, Versnel MA, Drexhage HA, Cohen D. Increased level of serum cytokines, chemokines and adipokines in patients with schizophrenia is associated with disease and metabolic syndrome. Psychoneuroendocrinology in press.
12. Bianchi R., Adami C., Giambanco I., Donato R. S100B binding to RAGE in microglia stimulates COX-2 expression. J Leukoc Biol 2007, 81:108-118.
13. Borda T., Perez Rivera R., Joensen L., Gomez R.M., Sterin-Borda L. Antibodies against cerebral M1 cholinergic muscarinic receptor from schizophrenic patients: molecular interaction. J Immunol 2002, 168:3667-3674.
14. Bories G., Caiazzo R., Derudas B., Copin C., Raverdy V., Pigeyre M., et al. Impaired alternative macrophage differentiation of peripheral blood mononuclear cells from obese subjects. Diabetes & vascular disease research: Official Journal of the International Society of Diabetes and Vascular Disease 2012, 9:189-195.
15. Brown A.S. The risk for schizophrenia from childhood and adult infections. Am J Psychiatry 2008, 165:7-10.
16. Bruning J.C., Gautam D., Burks D.J., Gillette J., Schubert M., Orban P.C., et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000, 289:2122-2125.
17. Brzustowicz L.M., Simone J., Mohseni P., Hayter J.E., Hodgkinson K.A., Chow E.W., et al. Linkage disequilibrium mapping of schizophrenia susceptibility to the CAPON region of chromosome 1q22. Am J Hum Genet 2004, 74:1057-1063.
18. Buchholz S., Morrow A.F., Coleman P.L. Atypical antipsychotic-induced diabetes mellitus: an update on epidemiology and postulated mechanisms. Intern Med J 2008, 38:602-606.
19. Buchsbaum M.S., Buchsbaum B.R., Hazlett E.A., Haznedar M.M., Newmark R., Tang C.Y., et al. Relative glucose metabolic rate higher in white matter in patients with schizophrenia. Am J Psychiatry 2007, 164:1072-1081.
20. Bushe C.J., Bradley A.J., Doshi S., Karagianis J. Changes in weight and metabolic parameters during treatment with antipsychotics and metformin: do the data inform as to potential guideline development? A systematic review of clinical studies. Int J Clin Pract 2009, 63:1743-1761.
21. Busse S., Busse M., Schiltz K., Bielau H., Gos T., Brisch R., et al. Different distribution patterns of lymphocytes and microglia in the hippocampus of patients with residual versus paranoid schizophrenia: further evidence for disease course-related immune alterations?. Brain Behav Immun 2012, 26:1273-1279.
22. Calamito M., Juntilla M.M., Thomas M., Northrup D.L., Rathmell J., Birnbaum M.J., et al. Akt1 and Akt2 promote peripheral B-cell maturation and survival. Blood 2010, 115:4043-4050.
23. Chiu H.J., Loh el W., Lan T.H., Sou J.H., Hsieh H.C., Hu T.M. Increase of incidence of impaired fasting glucose in young schizophrenia patients. Psychiatry Clin Neurosci 2009, 63:127-128.
24. Chowdari K.V., Mirnics K., Semwal P., Wood J., Lawrence E., Bhatia T., et al. Association and linkage analyses of RGS4 polymorphisms in schizophrenia. Hum Mol Genet 2002, 11:1373-1380.
25. Crammer J.L. Insulin coma therapy for schizophrenia. J R Soc Med 2000, 93:332-333.
26. Cummings D.E., Foster K.E. Ghrelin-leptin tango in body-weight regulation. Gastroenterology 2003, 124:1532-1535.
27. Di Lorenzo A., Fernandez-Hernando C., Cirino G., Sessa W.C., et al. Akt1 is critical for acute inflammation and histamine-mediated vascular leakage. Proc Natl Acad Sci U S A 2009, 106:14552-14557.
28. Donato R. RAGE: a single receptor for several ligands and different cellular responses: the case of certain S100 proteins. Curr Mol Med 2007, 7:711-724.
29. Doorduin J., et al. Neuroinflammation in schizophrenia-related psychosis: a PET study. J Nucl Med 2009, 50:1801-1807.
30. Dover G.J. The Barker hypothesis: how pediatricians will diagnose and prevent common adult-onset diseases. Trans Am Clin Climatol Assoc 2009, 120:199-207.
31. Drexhage R.C., et al. The mononuclear phagocyte system and its cytokine inflammatory networks in schizophrenia and bipolar disorder. Expert Rev Neurother 2010, 10:59-76.
32. Eaton W.W., et al. Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord 2010, 12:638-646.
33. Ebenbichler C.F., et al. Olanzapine induces insulin resistance: results from a prospective study. J Clin Psychiatry 2003, 64:1436-1439.
34. Edlinger M., et al. Treatment of antipsychotic-associated hyperglycemia with pioglitazone: a case series. J Clin Psychopharmacol 2007, 27:403-404.
35. Emamian E.S., et al. Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat Genet 2004, 36:131-137.
36. Evers S.S., et al. Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats. Pharmacol Biochem Behav 2010, 97:163-169.
37. Fatemi S.H., et al. Human influenza viral infection in utero alters glial fibrillary acidic protein immunoreactivity in the developing brains of neonatal mice. Mol Psychiatry 2002, 7:633-640.
38. Fatemi S.H., et al. Maternal infection leads to abnormal gene regulation and brain atrophy in mouse offspring: implications for genesis of neurodevelopmental disorders. Schizophr Res 2008, 99:56-70.
39. Fayard E., et al. Deletion of PKBalpha/Akt1 affects thymic development. PLoS One 2007, 2:e992.
40. Fernandez-Egea E., et al. Glucose abnormalities in the siblings of people with schizophrenia. Schizophr Res 2008, 103:110-113.
41. Fontana L., et al. Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes 2007, 56:1010-1013.
42. Frölich L., et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 1998, 105:423-438.
43. Fucetola R., et al. Age- and dose-dependent glucose-induced increases in memory and attention in schizophrenia. Psychiatry Res 1999, 88:1-13.
44. Ginhoux F., et al. Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science 2010, 330:841-845.
45. Gold P.E., et al. Glucose effects on memory: behavioral and pharmacological characteristics. Behav Neural Biol 1986, 46:145-155.
46. Goncalves C.A., et al. Adipocytes as an important source of serum S100B and possible roles of this protein in adipose tissue. Cardiovasc Psychiatry Neurol 2010, 7. (Article ID 790431:7 pages). 10.1155/2010/790431.
47. Gough S.C., O'Donovan M.C. Clustering of metabolic comorbidity in schizophrenia: a genetic contribution?. J Psychopharmacol 2005, 19:47-55.
48. Grill H.J., Kaplan J.M. The neuroanatomical axis for control of energy balance. Front Neuroendocrinol 2002, 23:2-40.
49. Grundy S.M., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol 2004, 24:e13-e18.
50. Guest P.C., et al. Increased levels of circulating insulin-related peptides in first onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 2010, 15:118-119.
51. Hauner H., et al. Effects of tumour necrosis factor alpha (TNF alpha) on glucose transport and lipid metabolism of newly-differentiated human fat cells in cell culture. Diabetologia 1995, 38:764-771.
52. Hegele R.A., et al. Lamin A/C mutation in a woman and her two daughters with Dunnigan-type partial lipodystrophy and insulin resistance. Diabetes Care 2000, 23:258-259.
53. Henderson D.C., et al. A double-blind, placebo-controlled trial of rosiglitazone for clozapine-induced glucose metabolism impairment in patients with schizophrenia. Acta Psychiatr Scand 2009, 119:457-465.
54. Hirayama I., et al. Insulin receptor-related receptor is expressed in pancreatic beta-cells and stimulates tyrosine phosphorylation of insulin receptor substrate-1 and -2. Diabetes 1999, 48:1237-1244.
55. Holmes E., et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 2006, 3:e327.
56. Juckel G., et al. Microglial activation in a neuroinflammational animal model of schizophrenia - a pilot study. Schizophr Res 2011, 131:96-100.
57. Juntilla M.M., et al. Akt1 and Akt2 are required for alphabeta thymocyte survival and differentiation. Proc Natl Acad Sci U S A 2007, 104:12105-12110.
58. Kirkpatrick B., et al. Differences in glucose tolerance between deficit and nondeficit schizophrenia. Schizophr Res 2009, 107:122-127.
59. Lai W.S., et al. Akt1 deficiency affects neuronal morphology and predisposes to abnormalities in prefrontal cortex functioning. Proc Natl Acad Sci U S A 2006, 103:16906-16911.
60. Leonard B.E., et al. The metabolic syndrome in schizophrenia: is inflammation a contributing cause?. J Psychopharmacol 2012, 26:33-41.
61. Lieberman J.A., et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-1223.
62. Lin Y.T., Liao S.C. Hashimoto encephalopathy presenting as schizophrenia-like disorder. Cogn Behav Neurol 2009, 22:197-201.
63. Lindholm E., et al. Linkage analysis of a large Swedish kindred provides further support for a susceptibility locus for schizophrenia on chromosome 6p23. Am J Med Genet 1999, 88:369-377.
64. Lofgren P., et al. Secretion of tumor necrosis factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue. Diabetes 2000, 49:688-692.
65. Luo Z.C., et al. Mechanisms of developmental programming of the metabolic syndrome and related disorders. World J Diab 2010, 1:89-98.
66. Magistretti P.J., et al. Brain energy metabolism: an integrated cellular perspective. Psychopharmacology: the fourth generation of progress 1995, 657-667. Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
67. Maxeiner H.G., et al. Flow cytometric analysis of T cell subsets in paired samples of cerebrospinal fluid and peripheral blood from patients with neurological and psychiatric disorders. Brain Behav Immun 2009, 23:134-142.
68. McGowan M.K., et al. Chronic intrahypothalamic infusions of insulin or insulin antibodies alter body weight and food intake in the rat. Physiol Behav 1992, 51:753-766.
69. McIntyre R.S., et al. Mood and psychotic disorders and type 2 diabetes: a metabolic triad. Can J Diab 2005, 29:122-132.
70. Menendez J.A., Atrens D.M. Insulin and the paraventricular hypothalamus: modulation of energy balance. Brain Res 1991, 555:193-201.
71. Meshkani R., Adeli K. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease. Clin Biochem 2009, 42:1331-1346.
72. Meyer U., Feldon J. Neural basis of psychosis-related behaviour in the infection model of schizophrenia. Behav Brain Res 2009, 204:322-334.
73. Miller B.J., et al. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-671.
74. Mitchell AJ, et al. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders - a systematic review and meta-analysis. Schizophr Bull in press.
75. Mitelman S.A., et al. Metabolic disconnection between the mediodorsal nucleus of the thalamus and cortical Brodmann's areas of the left hemisphere in schizophrenia. Am J Psychiatry 2005, 162:1733-1735.
76. Mozo J., et al. Thermoregulation: what role for UCPs in mammals and birds?. Biosci Rep 2005, 25:227-249.
77. Myint A.M. Kynurenines: from the perspective of major psychiatric disorders. FEBS J 2012, 279:1375-1385.
78. Narayanan S.P., et al. Akt signals through the mammalian target of rapamycin pathway to regulate CNS myelination. J Neurosci 2009, 29:6860-6870.
79. Netto C.B., et al. Serum S100B protein is increased in fasting rats. Arch Med Res 2006, 37:683-686.
80. Newcomer J.W. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry 2007, 68(Suppl. 4):8-13.
81. Newcomer J.W., et al. Glucose-induced increase in memory performance in patients with schizophrenia. Schizophr Bull 1999, 25:321-335.
82. Nikkila H., et al. Abnormal distributions of T-lymphocyte subsets in the cerebrospinal fluid of patients with acute schizophrenia. Schizophr Res 1995, 14:215-221.
83. Nikkilä H.V., et al. Accumulation of macrophages in the CSF of schizophrenic patients during acute psychotic episodes. Am J Psychiatry 1999, 156:1725-1729.
84. Pacheco-Lopez G, et al. Priming ofmetabolic dysfunctions by prenatal immune activation in mice: relevance to schizophrenia. Schizophr Bull in press.
85. Peters A., et al. The selfish brain: competition for energy resources. Neurosci Biobehav Rev 2004, 28:143-180.
86. Peters A., et al. Causes of obesity: looking beyond the hypothalamus. Prog Neurobiol 2007, 81:61-88.
87. Piontkewitz Y., et al. Effects of risperidone treatment in adolescence on hippocampal neurogenesis, parvalbumin expression, and vascularization following prenatal immune activation in rats. Brain Behav Immun 2012, 26:353-363.
88. Pont-Lezica L., et al. Physiological roles of microglia during development. J Neurochem 2011, 119:901-908.
89. Porte D., et al. Insulin signaling in the central nervous system: a critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 2005, 54:1264-1276.
90. Potvin S., et al. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:801-808.
91. Radewicz K., et al. Increase in HLA-DR immunoreactive microglia in frontal and temporal cortex of chronic schizophrenics. J Neuropathol Exp Neurol 2000, 59:137-150.
92. Ragland J.D., et al. Functional magnetic resonance imaging of internal source monitoring in schizophrenia: recognition with and without recollection. Schizophr Res 2006, 87:160-171.
93. Rolfe D.F., Brown G.C. Cellular energy utilization and molecular origin of standard metabolic rate in mammals. Physiol Rev 1997, 77:731-758.
94. Rothermundt M., et al. Increased S100B blood levels in unmedicated and treated schizophrenic patients are correlated with negative symptomatology. Mol Psychiatry 2001, 6:445-449.
95. Rothermundt M., et al. Glial cell dysfunction in schizophrenia indicated by increased S100B in the CSF. Mol Psychiatry 2004, 9:897-899.
96. Ryan M.C., et al. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003, 160:284-289.
97. Saddichha S., et al. Diabetes and schizophrenia - effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand 2008, 117:342-347.
98. Sakaguchi S., et al. Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
99. Salmi P., et al. Antagonism by SCH 23390 of clozapine-induced hypothermia in the rat. Eur J Pharmacol 1994, 253:67-73.
100. Scheen A.J., De Hert M.A. Abnormal glucose metabolism in patients treated with antipsychotics. Diabetes Metab 2007, 33:169-175.
101. Schlegelmilch T., et al. Microglia in the developing brain: from immunity to behaviour. Curr Opin Neurobiol 2011, 21:5-10.
102. Schroeter M.L., Steiner J. Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders. Mol Psychiatry 2009, 14:235-237.
103. Schwarcz R., et al. Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci 2012, 13:465-477.
104. Shim W.S., et al. The association of total and differential white blood cell count with metabolic syndrome in type 2 diabetic patients. Diabetes Res Clin Pract 2006, 73:284-291.
105. Sicras-Mainar A, et al. C-reactive protein as a marker of cardiovascular disease in patients with a schizophrenia spectrum disorder treated in routine medical practice. Eur Psychiatry in press.
106. Spelman L.M., et al. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 2007, 24:481-485.
107. Stahl S.M., et al. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatr Scand 2009, 119:171-179.
108. Steen E., et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes?. J Alzheimers Dis 2005, 7:63-80.
109. Stefanidis A., et al. The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity (Silver Spring) 2009, 17:16-24.
110. Stefansson H., et al. Common variants conferring risk of schizophrenia. Nature 2009, 460:744-747.
111. Steiner J., et al. Distribution of HLA-DR-positive microglia in schizophrenia reflects impaired cerebral lateralization. Acta Neuropathol 2006, 112:305-316.
112. Steiner J., et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. J Psychiatr Res 2008, 42:151-157.
113. Steiner J., et al. A new pathophysiological aspect of S100B in schizophrenia: potential regulation of S100B by its scavenger soluble RAGE. Biol Psychiatry 2009, 65:1107-1110.
114. Steiner J., et al. S100B serum levels are closely correlated with body mass index: an important caveat in neuropsychiatric research. Psychoneuroendocrinology 2010, 35:321-324.
115. Steiner J., et al. Elevated S100B levels in schizophrenia are associated with insulin resistance. Mol Psychiatry 2010, 15:3-4.
116. Steiner J., et al. Human CD8(+) T cells and NK cells express and secrete S100B upon stimulation. Brain Behav Immun 2011, 25:1233-1241.
117. Steiner J., et al. Bridging the gap between the immune and glutamate hypotheses of schizophrenia and major depression: potential role of glial NMDA receptor modulators and impaired blood-brain barrier integrity. World J Biol Psychiatry 2012, 13:482-492.
118. Steiner J., et al. Increased S100B+ NK cell counts in acutely ill schizophrenia patients are correlated with the free cortisol index, but not with S100B serum levels. Brain Behav Immun 2012, 26:564-567.
119. Steiner J, et al. Increased prevalence of diverse NMDA receptor antibodies in patients with an initial diagnosis of schizophrenia: specific relevance of IgG NR1a antibodies for distinction from NMDA receptor encephalitis. Arch Gen Psychiatry. in press.
120. Steinman R.M., et al. Dendritic cell function in vivo during the steady state: a role in peripheral tolerance. Ann N Y Acad Sci 2003, 987:15-25.
121. Sunram-Lea S.I., et al. The effect of retrograde and anterograde glucose administration on memory performance in healthy young adults. Behav Brain Res 2002, 134:505-516.
122. Sutton L.P., Rushlow W.J. The effects of neuropsychiatric drugs on glycogen synthase kinase-3 signaling. Neuroscience 2011, 199:116-124.
123. Tanaka S., et al. Autoantibodies against four kinds of neurotransmitter receptors in psychiatric disorders. J Neuroimmunol 2003, 141:155-164.
124. Torrey E.F., et al. Cytomegalovirus and schizophrenia. CNS Drugs 2006, 20:879-885.
125. Tremblay M.E., Majewska A.K. A role for microglia in synaptic plasticity?. Commun Integr Biol 2011, 4:220-222.
126. Tsutsui K., et al. Anti-NMDA-receptor antibody detected in encephalitis, schizophrenia, and narcolepsy with psychotic features. BMC Psychiatry 2012, 12:37.
127. Valassi E., et al. Neuroendocrine control of food intake. Nutr Metab Cardiovasc Dis 2008, 18:158-168.
128. van Berckel B.N., et al. Microglia activation in recent-onset schizophrenia: a quantitative (R)-[11C]PK11195 positron emission tomography study. Biol Psychiatry 2008, 64:820-822.
129. van Beveren N.J., et al. Marked reduction of AKT1 expression and deregulation of AKT1-associated pathways in peripheral blood mononuclear cells of schizophrenia patients. PLoS One 2012, 7:e32618.
130. Van den Bossche J., et al. Regulation and function of the E-cadherin/catenin complex in cells of the monocyte-macrophage lineage and DCs. Blood 2012, 119:1623-1633.
131. van der Pal R.H., et al. Effects of insulin and insulin-like growth factor (IGF-I) on oligodendrocyte-enriched glial cultures. J Neurosci Res 1988, 19:483-490.
132. van Os J., Kapur S. Schizophrenia. Lancet 2009, 374:635-645.
133. Wang H., et al. Coexistences of insulin signaling-related proteins and choline acetyltransferase in neurons. Brain Res 2009, 1249:237-243.
134. Weinberger D.R. Implications of normal brain development for the pathogenesis of schizophrenia. Arch Gen Psychiatry 1987, 44:660-669.
135. Weiss A.P., et al. Impaired hippocampal function during the detection of novel words in schizophrenia. Biol Psychiatry 2004, 55:668-675.
136. Winter C., et al. Prenatal immune activation leads to multiple changes in basal neurotransmitter levels in the adult brain: implications for brain disorders of neurodevelopmental origin such as schizophrenia. Int J Neuropsychopharmacol 2009, 12:513-524.
137. Xu H., et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003, 112:1821-1830.
138. Yolken R.H., Torrey E.F. Viruses, schizophrenia, and bipolar disorder. Clin Microbiol Rev 1995, 8:131-145.
139. Zhao Z., et al. Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res 2006, 84:1-14.
140. Zierhut K., et al. The role of hippocampus dysfunction in deficient memory encoding and positive symptoms in schizophrenia. Psychiatry Res Neuroimaging 2010, 183:187-194.